/** Title: Blue Jet Healthcare FY26: Contrast Media Strength Offsets PI Volatility */

Blue Jet Healthcare FY26: Contrast Media Strength Offsets PI Volatility

Blue Jet Healthcare closed FY26 with a mixed operating picture. Revenue from operations for the year came in at INR 947.3 crores, down 8 percent versus FY25. EBITDA stood at INR 294.1 crores with a 31.0 percent margin, and PAT was INR 247.8 crores with a 26.2 percent margin.

The year was shaped by two opposing forces. The contrast media intermediates business delivered strong growth and helped stabilize overall performance. Meanwhile, the pharma intermediates and API segment saw a sharp decline, which management attributed to customer-side inventory normalization and order phasing in select accounts.

In Q4 FY26, revenue from operations was INR 234.7 crores, up 22 percent sequentially, supported by higher sales of advanced contrast media intermediates. Profitability improved QoQ as well, with EBITDA margin rising to 30.4 percent and PAT margin to 27.4 percent.

FY26 performance: stable gross margin, lower operating leverage

The company reported a FY26 gross margin of 54.0 percent compared to 55.2 percent in FY25. The EBITDA margin fell from 36.7 percent to 31.0 percent, which management linked to lower PI and API volumes and higher operating costs.

Other income increased to INR 68.7 crores in FY26 from INR 46.3 crores in FY25, largely due to foreign exchange gains. The company highlighted that rupee depreciation supported export realizations and partly offset raw material inflation seen late in the year.

Segment mix: contrast media outperformance, PI normalization underway

Blue Jet operates across three product categories: contrast media intermediates, high intensity sweeteners, and pharma intermediates and APIs. In FY26, contrast media intermediates contributed 52.5 percent of revenue, high intensity sweeteners 13.9 percent, and pharma intermediates and APIs 31.6 percent.

Contrast media intermediates was the standout segment. FY26 revenue from this category rose 23 percent to INR 495.1 crores. In Q4 FY26, contrast media intermediates revenue was INR 192.8 crores, up 91 percent year on year, and management clarified on the call that the quarter’s performance largely reflected current-quarter order flow rather than goods-in-transit adjustments.

The PI and API segment was the weak spot. Q4 FY26 revenue in this category dropped to INR 2.4 crores versus INR 195.9 crores in Q4 FY25. Management attributed the fall to negligible sales of a key molecule due to customer destocking and inventory normalization. In the earnings call, management stated that destocking is now behind the segment and indicated improved shipment trends and better order visibility as FY27 begins.

High intensity sweeteners remained relatively stable for the year at INR 131.4 crores, down 2 percent YoY. The CFO noted pricing pressure from imports in this category and said the company would remain opportunistic.

Strategy and investments: Vizag, Mahad backward integration, and Hyderabad R&D

FY26 was positioned by management as a platform-building year. The company highlighted progress across manufacturing expansion and R&D capability upgrades.

A key milestone is the Vizag greenfield project. Management stated on the call that project activities have commenced following the groundbreaking ceremony. The Vizag site spans approximately 100 acres and is planned in phases. Phase 1 is intended to include dedicated manufacturing blocks for contrast media intermediates, high intensity sweeteners, and pharma intermediates. Management disclosed an envisaged capex of approximately INR 1,000 crores over roughly 3 years.

The company is also progressing on the Mahad Unit 3 site, where it is developing a backward integration project for a key raw material in its contrast media portfolio. Management said the Mahad facility is in the final stages of completion and is expected to commence production in H2 FY27. The company expects a slow ramp-up, with fuller benefits likely after about a year.

On R&D, the company is developing a Hyderabad R&D centre. The investor presentation states civil construction has commenced and is expected to be completed on or before September 2026, along with the hiring of key resources. On the earnings call, management indicated planned investment of about INR 40 crores and said the centre is expected to go live in H2 FY27. The R&D focus areas mentioned include peptide-related intermediates, GLP-1 linked opportunities, and biocatalysts.

Capex for FY27 is expected to be elevated. Management stated it proposes to spend approximately INR 400 crores in FY27 towards the Vizag greenfield project, completion of Mahad, and additions at Ambernath.

What management emphasized for FY27

Management did not provide formal financial guidance, but it highlighted several forward indicators.

In contrast media, the CFO stated that a key customer’s annual forecast points to mid-single digit growth for FY27 on the flagship product. Management also expects new launches, with the COO stating that 3 to 4 new product launches are expected in the contrast media segment during the current year. Management also referred to validations spanning iodinated and gadolinium molecules and indicated expectations of a commercial launch during FY27.

In the PI and API segment, management reiterated that inventory normalization is complete and that it expects normalization in performance as orders convert to shipments. The company also disclosed it is tracking around 20 active RFPs, including intermediates linked to GLP-1 programs and peptide building blocks, and expects two opportunities to move into commercialization during the current year.

On the balance sheet, the company ended FY26 debt-free. It reported liquid financial assets of INR 400 crores at year-end, and the presentation reported cash and cash equivalents plus treasury investments of INR 3,619 million as of March 31, 2026.

Takeaways

FY26 showed the strength of Blue Jet’s contrast media intermediates franchise, with growth in advanced intermediates offsetting weakness in PI and API. The near-term investor focus is likely to remain on two areas: how quickly PI and API normalize as customer inventory effects fade, and how effectively the company executes its multi-year capacity and R&D expansion program.

With a debt-free balance sheet, disclosed capex plans for Vizag and Hyderabad, and a stated timeline for Mahad commissioning in H2 FY27, FY27 appears positioned as a transition year. The company expects continued contrast media momentum and anticipates that pipeline work and validations will begin translating into broader commercialization over time.